Study: Casdatifan demonstrates durable tumor responses in heavily pretreated patients with advanced kidney cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 31-Oct-2026 16:15 ET (31-Oct-2026 20:15 GMT/UTC)
Study: Casdatifan, a new generation HIF-2α blocker, demonstrated durable tumor responses in heavily pretreated patients with advanced kidney cancer. The findings link treatment activity to HIF-2α biology and biomarker changes, supporting precision medicine approaches.
A University of Texas at Dallas researcher has received more than $1 million in grants from the Cancer Prevention & Research Institute of Texas (CPRIT) to develop treatments for solitary fibrous tumor, or SFT. The rare cancer develops when two genes, NAB2 and STAT6, become fused together, resulting in signals that initiate cancer-cell growth. The cause is unknown. While no medications have been developed specifically for SFT, treatment typically involves surgery to remove the tumor and/or radiation.